Towards Healthcare

Cancer Diagnostics Key Players and Strategic Joint Ventures

Date : 11 November 2025

Cancer Diagnostics Market Companies

Market Growth

The global cancer diagnostics market size is calculated at USD 109.65 billion in 2024, grow to USD 116.42 billion in 2025, and is projected to reach around USD 199.54 billion by 2034, rising at a 6.17% CAGR for the forecasted period of 2025 to 2034.

Cancer Diagnostics Market Size 2024 - 2034

  • In February 2025, QIAGEN announced a collaboration with Tracer Biotechnologies and Foresight Diagnostics to expand its oncology diagnostics portfolio. The collaboration will enable the advancement of the use of minimal residual disease (MRD) testing in clinical trials to support co-development projects for companion diagnostics. (Source: Stock Titan)
  • In November 2024, Danaher Corporation revealed plans to launch two new Centers of Innovation in Diagnostics to support the progress of precision medicine. The first center, set to open in July in Newcastle, UK, will focus on collaborative research with top pharmaceutical companies and academic partners. This facility, hosted by Danaher’s subsidiary Leica Biosystems, will also function as the company’s first CLIA CAP-certified laboratory, emphasizing high standards in diagnostic testing and research.
  • In April 2023, Quest Diagnostics completed the full acquisition of Haystack Oncology in a cash-only deal to strengthen its capabilities in minimal residual disease (MRD) testing. The focus of this expansion is on improving early detection of MRD in patients treated for colorectal, breast, and lung cancers. Through this move, Quest aims to support better patient outcomes by identifying potential cancer recurrence sooner and guiding follow-up treatment more effectively.

Latest Announcement by Industry Leaders

In April 2025, TGH Onco-Life Cancer Centre launched a mobile van equipped with a breast cancer screening unit to promote early detection and awareness among women in rural and semi-urban Maharashtra. Supported by the Rotary Club of Talegaon, Dabhade, and donated by POSCO India, the van will provide free screenings and also visit large offices to reach underprivileged workers who often delay health check-ups. Sachin Deshmukh said, “For those in need, we also offer financial assistance and discounted treatments,” while Kamlesh Karle emphasized, “This unit is dedicated to serving the underprivileged, with a focus on early detection.”

Recent Developments in the Cancer Diagnostics Market

  • In May 2025, Sir H.N. Reliance Foundation Hospital announced the launch of South Asia’s first and fastest Genius AI 3D mammography system for breast cancer screening through cutting-edge imaging technology and AI-powered diagnostics. The system can diagnose breast cancer at an early sub-clinical stage within 3.7 seconds, enhancing patient comfort. (Source: Healthcare Radius)
  • In February 2023, F. Hoffmann-La Roche revealed it was strengthening its partnership with Janssen to further support personalized healthcare efforts. The focus of this extended collaboration is on creating companion diagnostics that can help deliver more effective, tailored treatments for patients. This move highlights both companies’ shared dedication to advancing individualized approaches in modern healthcare.
  • In July 2024, DELFI Diagnostics announced receiving equity investment from the Merck Global Health Innovation Fund. The investment will help accelerate the advancement of DELFI’s AI-powered fragmentomics platform designed for cancer screening. This partnership is focused on strengthening diagnostic technologies and improving the accuracy and effectiveness of cancer detection methods.

Partner with our experts to explore the Cancer Diagnostics Market at sales@towardshealthcare.com